Warner Chilcott announced the launch of a 200mg dosage strength for Doryx (doxycycline hyclate) delayed-release tablets.

Doryx is a tetracycline antibiotic indicated as adjunct treatment in severe acne, the treatment of tetracycline-susceptible infections including respiratory, genitourinary, rickettsial, trachoma, and for postexposure prophylaxis and treatment of anthrax.

RELATED: Infectious Diseases Resource Center

Doryx inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.

It has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria.

Doryx 200mg delayed-release tablets are available in 60-count bottles. Doryx is already available in 80mg, 100mg, and 150mg dosage strength tablets.

For more information call (800) 521-8813 or visit www.wcrx.com.